Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity
- PMID: 10553041
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity
Abstract
This study shows that removal of a T cell subpopulation can evoke effective tumor immunity in otherwise nonresponding animals. Elimination of CD25-expressing T cells, which constitute 5-10% of peripheral CD4+ T cells in normal naive mice, elicited potent immune responses to syngeneic tumors in vivo and eradicated them. The responses were mediated by tumor-specific CD8+ CTLs and tumor-nonspecific CD4-8- cytotoxic cells akin to NK cells. Furthermore, in vitro culture of CD25+4+ T cell-depleted splenic cell suspensions prepared from tumor-unsensitized normal mice led to spontaneous generation of similar CD4-8- cytotoxic cells capable of killing a broad spectrum of tumors; reconstitution of CD25+4+ T cells inhibited the generation. In this culture, self-reactive CD25-4+ T cells responding to self peptides/class II MHC complexes on APCs spontaneously proliferated upon removal of CD25+4+ T cells, secreting large amounts of IL-2. The IL-2 thus produced appeared to be responsible for the generation of CD4-8- NK cells as lymphokine-activated killer cells, because direct addition of an equivalent amount of IL-2 to the culture of CD4-8- cells generated similar lymphokine-activated killer/NK cells, whereas coculture of normal CD4-8- cells with CD25-4+ T cells from IL-2-deficient mice did not. Thus, removal of immunoregulatory CD25+4+ T cells can abrogate immunological unresponsiveness to syngeneic tumors in vivo and in vitro, leading to spontaneous development of tumor-specific effector cells as well as tumor-nonspecific ones. This novel way of evoking tumor immunity would help to devise effective immunotherapy for cancer in humans.
Similar articles
-
Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance.J Immunol. 1999 May 1;162(9):5317-26. J Immunol. 1999. PMID: 10228007
-
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.J Immunol. 1995 Aug 1;155(3):1151-64. J Immunol. 1995. PMID: 7636184
-
Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state.Int Immunol. 1998 Dec;10(12):1969-80. doi: 10.1093/intimm/10.12.1969. Int Immunol. 1998. PMID: 9885918
-
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.J Exp Med. 2001 Sep 17;194(6):823-32. doi: 10.1084/jem.194.6.823. J Exp Med. 2001. PMID: 11560997 Free PMC article.
-
Non-cytotoxic functions of CD8 T cells: "repentance of a serial killer".Front Immunol. 2022 Sep 12;13:1001129. doi: 10.3389/fimmu.2022.1001129. eCollection 2022. Front Immunol. 2022. PMID: 36172358 Free PMC article. Review.
Cited by
-
CD8+ T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by Tregs.Nat Commun. 2024 Mar 1;15(1):1900. doi: 10.1038/s41467-024-45625-0. Nat Commun. 2024. PMID: 38429261 Free PMC article.
-
Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances.Front Immunol. 2024 Feb 15;15:1354313. doi: 10.3389/fimmu.2024.1354313. eCollection 2024. Front Immunol. 2024. PMID: 38426090 Free PMC article. Review.
-
Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine.Nat Rev Clin Oncol. 2024 Feb 29. doi: 10.1038/s41571-024-00870-6. Online ahead of print. Nat Rev Clin Oncol. 2024. PMID: 38424196 Review.
-
Insight into the significance of Foxp3 + tumor-infiltrating lymphocytes in squamous cell lung cancer.Clin Transl Oncol. 2024 Feb 25. doi: 10.1007/s12094-024-03392-w. Online ahead of print. Clin Transl Oncol. 2024. PMID: 38402536
-
Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle.Front Immunol. 2023 Dec 22;14:1303935. doi: 10.3389/fimmu.2023.1303935. eCollection 2023. Front Immunol. 2023. PMID: 38187393 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous